Literature DB >> 9471138

Secondary conditions following spinal cord injury in a population-based sample.

R L Johnson1, K A Gerhart, J McCray, J C Menconi, G G Whiteneck.   

Abstract

This prospective study investigates the frequency of both medical and non-medical complications reported by the population based cohort of SCI survivors reported to the Colorado Spinal Cord Injury Early Notification System (ENS). Persons reported to the ENS between January 1 1986 and December 31 1993, representing the broad spectrum of all severities of spinal cord injury and potential complications, were solicited to participate in comprehensive follow-up interviews at their first, third and fifth year post injury. Hospitalizations of a week or longer were experienced by more than 10% of the participants at each of the three interview years. Similarly, the medical complications of spasticity or pain were reported by more than 25% of the participants, and pressure sores were reported by more than 10% at all three time periods. The chief non-medical complications (conditions) were financial concerns and transportation problems. Although these reported medical and non-medical complications present significant obstacles to be overcome, less than three percent of those surveyed at any of the time periods reported experiencing depression; and only 14% rated their quality of life as being poor.

Entities:  

Mesh:

Year:  1998        PMID: 9471138     DOI: 10.1038/sj.sc.3100494

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  47 in total

1.  Assessment of quality of life in relation to spasticity severity and socio-demographic and clinical factors among patients with spinal cord injury.

Authors:  Meltem Vural; Ebru Yilmaz Yalcinkaya; Evrim Coskun Celik; Berrin Gunduz; Ahmet Bozan; Belgin Erhan
Journal:  J Spinal Cord Med       Date:  2018-12-03       Impact factor: 1.985

2.  Assessment of physical function and secondary complications after complete spinal cord injury.

Authors:  Shauna Dudley-Javoroski; Richard K Shields
Journal:  Disabil Rehabil       Date:  2006-01-30       Impact factor: 3.033

Review 3.  Long term health outcomes after injury in working age adults: a systematic review.

Authors:  C M Cameron; E V Kliewer; D M Purdie; R J McClure
Journal:  J Epidemiol Community Health       Date:  2006-04       Impact factor: 3.710

4.  Segmental neuropathic pain does not develop in male rats with complete spinal transections.

Authors:  Charles H Hubscher; Ezidin G Kaddumi; Richard D Johnson
Journal:  J Neurotrauma       Date:  2008-10       Impact factor: 5.269

Review 5.  Chemodenervation for treatment of limb spasticity following spinal cord injury: a systematic review.

Authors:  J Lui; M Sarai; P B Mills
Journal:  Spinal Cord       Date:  2015-01-13       Impact factor: 2.772

6.  Secondary health conditions and disability among people with spinal cord injury: A prospective cohort study.

Authors:  Amy Richardson; Ari Samaranayaka; Martin Sullivan; Sarah Derrett
Journal:  J Spinal Cord Med       Date:  2019-03-18       Impact factor: 1.985

7.  Bacterial load of conditioned pressure ulcers is not a predictor for early flap failure in spinal cord injury.

Authors:  T Kamradt; S Klein; S Zimmermann; J Schröder-Braunstein; C H Fürstenberg; C Hensel; N Weidner; A Hug
Journal:  Spinal Cord       Date:  2017-01-10       Impact factor: 2.772

8.  The Spinal Cord Injury Spasticity Evaluation Tool: A Persian adaptation and validation study.

Authors:  Noureddin Nakhostin Ansari; Mina Kashi; Soofia Naghdi
Journal:  J Spinal Cord Med       Date:  2016-08-31       Impact factor: 1.985

Review 9.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Participation following traumatic spinal cord injury: an evidence-based review for research.

Authors:  Susan R Magasi; Allen W Heinemann; Gale G Whiteneck
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.